Topical 0.4% Ketorolac and Vitreoretinal Surgery
Information source: Emory University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Surgery
Intervention: Ketorolac (Drug)
Phase: Phase 2/Phase 3
Status: Completed
Sponsored by: Emory University Official(s) and/or principal investigator(s): Stephen J Kim, MD, Principal Investigator, Affiliation: Emory University
Summary
To determine whether use of topical 0. 4% ketorolac has any effect on pupil size during
vitreoretinal surgery.
Clinical Details
Official title: Topical 0.4% Ketorolac for the Inhibition of Miosis During Vitreoretinal Surgery: a Randomized, Placebo-controlled, Double-masked Study
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Primary outcome: Change in pupil size during vitreoretinal surgery
Secondary outcome: Postoperative pain and inflammation
Detailed description:
Other outcomes will be to assess postoperative pain and inflammation and visual acuity.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age of 18, routine elective vitrectomy
Exclusion Criteria:
- history of trauma, uveitis, prior intraocular surgery within 3 months, requirement of
mechanical pupil dilation, prior inclusion of other eye
Locations and Contacts
Emory Eye Clinic, Atlanta, Georgia 30322, United States
Additional Information
Starting date: November 2006
Last updated: May 12, 2014
|